William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.
William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.
Transcript
The COVID-19 pandemic has demonstrated the necessity for vaccines, antibodies, and other treatments, and the timeliness of their developments. What can be learned from this to take the next steps toward treatments and preventions for RSV?
Stinchfield: I think we have a bit of a Catch-22 with RSV. First of all, again, understanding that virus—the magnitude of its impact—and the way you do that is you have a good diagnostic test for it. We do have a good PCR [polymerase chain reacton] panel that we use in intensive care to say this child or this adult has a severe respiratory illness. What is it? Is it flu? Is it RSV? Is it adenovirus? There's a whole host of severe viruses. We also need that kind of diagnostic testing to be more accessible—much like we're seeing with COVID testing being done in our own homes so that parents could be able to say, "Can I send my child to daycare today? He's coughing, he's wheezing"—and the RSV rapid home tests, which I envision that doesn't exist at this point, but would be wonderful.
Some of the things we can learn from COVID-19 will be getting those rapid tests. I think what we did in health care was we'd say, "Well, there is no treatment. If there's no treatment, then why are you testing? What does it matter? We should just do symptomatic management." That's where the Catch-22 is. So we need better diagnostics, which can lead to better understanding of our impact, what ages are impacted, to what degree, and have the kind of data that we have right now of COVID-19 in disease in different age groups. Then we can also say, "This age group is most impacted. Let's target our vaccines to pregnant women or to people over 65 and then have that ongoing surveillance.." You can see these things are all related. Unless you have, really, a good understanding of your current epidemiology of it and that public health surveillance, it's hard then to get us into a place where we're using antivirals and, even more so, preventative things like vaccines and monoclonal antibodies.
Schaffner: Doctors respond best when they know what's causing an illness. So to say that a patient does not have flu, negative tests, does not have COVID, something else, doctors don't respond to that very well. They respond better if you can define the illness, right? "Yes, it's RSV." And I would emphasize that we need better, more accessible diagnostic testing. I think the tests ought to be, first of all, accurate; second of all, available; third, quick so we can get a rapid answer; and fourth, inexpensive. At the moment, we have those multiplex tests at our institutions, just as Patsy was describing. But they're generally discouraged for use except in seriously ill patients—very seriously ill patients, intensive care unit patients and the like—because they're rather expensive. What we need is more accessible, less expensive testing. When these new modalities of treatment and prevention come along, then we will be able to focus and see what the impact is, clinically and from a public health point of view.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More